KLASS 01 Trial Update: What You Need to Know About Laparoscopic Gastrectomy
"A closer look at the corrections in the KLASS 01 trial and what they mean for gastric adenocarcinoma treatment."
In the realm of surgical oncology, precision and accuracy are paramount. The Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) group's KLASS 01 trial aimed to compare the effectiveness of laparoscopic distal gastrectomy (LADG) with open distal gastrectomy (ODG) for gastric adenocarcinoma. This trial, published in the Annals of Surgical Treatment and Research, initially contained some inaccuracies regarding the number of recruited patients and participating institutions.
An erratum, a correction of errors in a published work, was later issued to address these discrepancies. This article delves into the specifics of the corrections made in the KLASS 01 trial and explores why such attention to detail is critical in medical research and patient care. For readers, understanding these nuances ensures informed perspectives on treatment options.
Gastric cancer, or stomach cancer, remains a significant global health challenge. Distal gastrectomy, the surgical removal of the lower portion of the stomach, is a common treatment for adenocarcinoma located in this region. The KLASS 01 trial sought to determine if a minimally invasive approach (LADG) could offer similar outcomes to the traditional open surgery (ODG), potentially with reduced recovery times and improved patient comfort.
KLASS 01 Trial Correction
A 2013 erratum addressed a correction to the number of patients recruited and participating institutions in the KLASS 01 trial. The original trial was a phase III prospective randomized comparison of laparoscopic and open distal gastrectomy for gastric adenocarcinoma. The erratum describes the trial note as published in volume 84, issue 2, of the February 2013 issue.
KLASS 01 Trial: Correcting the Record
The original KLASS 01 publication, as noted in the erratum, contained errors in the reported number of patients and participating centers. These errors, while seemingly minor, prompted a formal correction to maintain the integrity of the trial's findings. Here's a breakdown of the key changes:
- Number of Participating Institutions: The initial publication mentioned 12 participating institutions. The corrected number is 13 institutions.
Recent Reviews and the KLASS Trial Series
A Cochrane review on laparoscopic versus open gastrectomy for gastric cancer reports that one trial with 53 participants contributed no data to the review. A separate 2015 report describes minimally invasive esophagectomy in 54 patients with esophageal cancer, in a study of laparoscopic gastric tube formation with pyloromyotomy. A 2024 prospective randomized trial asks whether differences in invasiveness between totally laparoscopic and laparoscopy-assisted distal gastrectomy affect early surgical outcomes. The KLASS trial series began with KLASS 01 in 2006 and had reached its 14th series by December 2024, according to a 2025 review.
Evidence Across Cancer Stages
KLASS-01 investigated laparoscopic surgery for early gastric cancer, while researchers subsequently initiated KLASS-02 for locally advanced gastric cancer. The cited KLASS-02 report says laparoscopic surgery is an option in general practice for patients with stage I cancer indicated for distal gastrectomy. A 2019 randomized clinical trial examined whether long-term survival after laparoscopic distal gastrectomy for stage I gastric cancer was noninferior to survival after open distal gastrectomy.
Limits of the Listed Comparisons
The supplied sources for this subsection concern randomized controlled trials unrelated to gastrectomy. One article compares trials on very elderly subjects with trials on adults and reports a mean methodological quality score of 0.592 ± 0.116 for 84 matched RCT/C studies, with p = .466. The other describes cracked teeth with endodontitis or periapical disease randomized to one-visit or multiple-visit root canal treatment. These source details do not establish a comparison between laparoscopic and open gastrectomy.
Why These Corrections Matter for You
For patients facing a diagnosis of gastric adenocarcinoma, the KLASS 01 trial offers valuable insights into the potential benefits of laparoscopic surgery. While the corrections themselves might seem like minor adjustments, they underscore the importance of rigorous methodology and data accuracy in medical research. These refinements help ensure that the trial's conclusions are reliable and can be used to guide treatment decisions with confidence. It also demonstrates the rigorous oversight and commitment to accuracy that guide clinical research.
Five-Year CLASS-01 Follow-Up
A report dated December 5, 2020, presents five-year overall survival data from the multicenter randomized controlled CLASS-01 trial. The source says earlier data from the trial showed that laparoscopic distal gastrectomy did not result in inferior disease-free survival at three years compared with open distal gastrectomy. The supplied snippet identifies the follow-up outcome but does not provide the five-year results.
Survival Findings in KLASS-01
The KLASS-01 trial reported similar overall and cancer-specific survival rates for patients who received laparoscopic or open distal gastrectomy. Its authors concluded that laparoscopic distal gastrectomy is an oncologically safe alternative to open surgery for stage I gastric cancer. The supplied source identifies the trial registration as a ClinicalTrials.gov identifier but does not include the identifier itself.